U.S. Court of Appeals Denies Appeal in Baraclude Patent Case

Thursday, June 12, 2014 3:41 pm EDT

Dateline:

NEW YORK

Public Company Information:

NYSE:
BMY

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid.

The company is reviewing the decision and considering all its legal options.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:

Bristol-Myers Squibb
Media
Frederick Egenolf, 609-252-4875
frederick.egenolf@bms.com
or
Investor Relations
Ryan Asay, 609-252-5020
ryan.asay@bms.com
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

Search Press Releases

Reset



Subscribe to E-Mail Alerts

Business Wire NewsHQ℠